85.59.B - Other out-of-school forms of education, not elsewhere classified
46.46.Z - Wholesale of pharmaceutical goods
46.90.Z - Non-specialised wholesale trade
70.22.Z - Business and other management consultancy activities
72.11.Z - Research and experimental development on biotechnology
72.19.Z - Other research and experimental development on natural sciences and engineering
72.20.Z - Research and experimental development on social sciences and humanities
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
82.99.Z - Other business support service activities not elsewhere classified
96.09.Z - Other personal service activities not elsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 0 | 0 | -0,1 | -378,1 |
EBITDA | 0 | 0,1 | -0 | -163 |
Short time liabilities | 0,3 | 0,1 | 0,1 | -22 |
Equity capital | 0,4 | 0,5 | 0,3 | -29,8 |
Operating profit (EBIT) | 0 | 0,1 | -0,1 | -368,7 |
Assets | 0,9 | 0,9 | 1 | 6,7 |
Net profit (loss) | 0 | 0 | -0,1 | -378,1 |
Cash | 0,2 | 0,5 | 0,4 | -18 |
Liabilities and provisions for liabilities | 0,5 | 0,5 | 0,7 | 41,6 |
Net income from sale | 2,1 | 2,4 | 2,3 | -5,4 |
Working assets | 0,8 | 0,9 | 0,5 | -42,1 |
Depreciation | 0 | 0 | 0,1 | 262,5 |
% | % | % | p.p. | |
Profitability of capital | 1 | 10,7 | -42,5 | -53,2 |
Equity capital to total assets | 45,7 | 48,9 | 32,1 | -16,8 |
Gross profit margin | 0,2 | 2,1 | -6,1 | -8,2 |
EBITDA Margin | 1,6 | 3,2 | -2,1 | -5,3 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 49 | 16 | 14 | -2 |
Current financial liquidity indicator | 1.6442627906799316 | 1.8056033849716187 | 0.7388412952423096 | -1,1 |
Net dept to EBITDA | -6.363920211791992 | -7.028653621673584 | 9.155952453613281 | 16,2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane